ClinicalTrials.Veeva

Menu

NIV NAVA Versus NIV-PS in Pediatric Patients - Pilot Study (NINAVAPed)

M

Madrid Health Service

Status

Unknown

Conditions

Acute Respiratory Failure

Study type

Observational

Funder types

Other

Identifiers

NCT01873261
HULP-PI-3750

Details and patient eligibility

About

This pilot study will be an observational no randomize study in which the NiNAVAped protocol will be applied solely to the NIV NAVA arm.

Full description

This pilot study will be an observational no randomize study in which the NiNAVAped protocol will be applied solely to the NIV NAVA arm.

Every PICU will have to include 3 patients in the Pilot study before starting the clinical trial, which means that the pilot study will involve a maximum of 60 patients.

Should the Pilot study reveal deficiencies in the NiNAVAped design, the protocol would be improved accordingly.

There will be a specific consent document during the Pilot study. The Pilot study will be published in a scientific journal.

Enrollment

60 estimated patients

Sex

All

Ages

1 month to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age: > 1 month age to 18 years
  • Moderate/severe Pediatric Acute Respiratory failure of any origin evaluated after a period of respiratory stabilization (aspiration of secretions, physiotherapy, oxygen and nebulized therapy) when the attending pediatric intensive care physician believes that the patient is likely to require endotracheal intubation (ETI).
  • Non intubated
  • Admitted to the PICU
  • Minimally agitated/sedated: between -2 and +2 on the Richmond agitation-sedation scale (Table 2)

Exclusion criteria

  1. Patients younger than 1 month or older than 18 year
  2. Patients who need immediate endotracheal intubation: i.e.: Severe ARF with signs of exhaustion
  3. Facial trauma/burns
  4. Recent facial, upper way, or upper gastrointestinal tract surgery excepting gastrostomy for feeding
  5. Fixed obstruction of the upper airway
  6. Inability to protect airway
  7. Life threatening hypoxemia defined as SpaO2 <90% with FiO2 > 0.8 on hi-flow oxygen.
  8. Hemodynamic instability: refractory at volume expansion >60 ml/kg and dopamine >10 mcg/kg/min
  9. Impaired consciousness defined as Glasgow coma scale < 10.
  10. Bowel obstruction.
  11. Untreated pneumothorax.
  12. Poor short term prognosis (high risk of death in the next 3 months)
  13. Known esophageal problem (hiatal hernia, esophageal varicosities)
  14. Active upper gastro-intestinal bleeding or any other contraindication to the insertion of a NG tube.
  15. Neuromuscular disease
  16. Vomiting
  17. Cough or gag reflex impairment.
  18. Cyanotic congenital heart disease.
  19. Complete absence of cooperation
  20. This patient has been included (randomized) previously in the study

Trial contacts and locations

1

Loading...

Central trial contact

Pedro De la Oliva, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems